Kappa Opioid Ligands for Dysphoria-Aware Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for addiction, depression, anxiety, and neurological disorders such as epilepsy and Alzheimer's disease are inadequate in addressing the dysphoric elements and dysregulation of the dynorphin-Kappa opioid system, which contribute to stress-induced relapse and neuroplasticity disruption.
Innovation Solution
Development of novel kappa opioid receptor ligands that modulate the kappa opioid receptor system to address dysphoric elements and dysregulation, providing therapeutic benefits through compounds of formula (I) that can be administered to patients to modulate the receptor and provide neuroprotection, treat dissociative disorders, and induce diuresis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for addiction and neurological disorders are used, then some therapeutic effects are achieved, but they are inadequate in addressing dysphoric elements and dysregulation of the dynorphin-Kappa opioid system
Solution Approach 1:
The patent develops novel kappa opioid ligands with modified chemical structures (formula I) that change the pharmacological parameters of receptor interaction. These structural modifications enable the ligands to selectively modulate the kappa opioid system, addressing dysphoric elements that current treatments fail to address, while maintaining therapeutic effectiveness for addiction and neurological disorders
2Reliability
If kappa opioid receptor agonists are used to treat addiction, then stress-induced relapse may be reduced, but dysphoric elements and neuroplasticity disruption may worsen
Solution Approach 1:
Instead of using traditional kappa opioid agonists that activate the receptor and produce dysphoric effects, the patent employs novel ligands that selectively modulate the receptor in a way that blocks stress-induced activation without producing dysphoria. This inverted approach addresses the harmful effects while maintaining the beneficial prevention of relapse
3Reliability
If dynorphin-KOR system activation is increased to control addiction, then stress-induced drug seeking may be reduced, but neuroplasticity disruption and dysphoria may increase
Solution Approach 1:
The novel ligands act as intermediary substances that selectively interfere with pathologic dynorphin-KOR interactions without blocking all KOR activity. This mediated approach allows the system to maintain normal neuroplasticity functions while preventing stress-induced drug seeking behavior, avoiding the dysphoric effects of complete system activation
Data Source
AI summary
The invention provides novel ligands of Kappa (κ) opioid receptors, such as can be used to modulate a Kappa opioid receptor. Methods of synthesis and methods of use are also provided. Compounds of the invention can be used therapeutically in the treatment of dissociative disorders or pain, or to provide neuroprotection, or to induce diuresis, or to modulate the immune system, or for treatment of one or more of an affective disorders comprising depression or stress/anxiety; an addictive disorder; alcoholism, epilepsy; a cognition deficiency; schizophrenia; Alzheimer's disease; or pain.